Search

Now showing items 1-10 of 82

HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact

Martin, NK; Foster, GR; Vilar, J; Ryder, S; Cramp, ME; Gordon, F; Dillon, JF; Craine, N; Busse, H; Clements, A;... (2015-04)

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection

Agarwal, K; Fung, SK; Nguyen, TT; Cheng, W; Sicard, E; Ryder, SD; Flaherty, JF; Lawson, E; Zhao, S; Subramanian, GM;... (2015-03)

Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection.

Agarwal, K; Fung, SK; Nguyen, TT; Cheng, W; Sicard, E; Ryder, SD; Flaherty, JF; Lawson, E; Zhao, S; Subramanian, GM;... (2015-03)

BACKGROUND & AIMS: Tenofovir alafenamide, a phosphonate prodrug of tenofovir with greater plasma stability than tenofovir disoproxil fumarate, provides efficient delivery of active drug to hepatocytes at reduced systemic ...

Development and Validation of a "Capture-Fusion" Model to Study Drug Sensitivity of Patient-Derived Hepatitis C

Cunningham, ME; Javaid, A; Waters, J; Davidson-Wright, J; Wong, JLC; Jones, M; Foster, GR (2015-04)

Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review

Owiti, JA; Greenhalgh, T; Sweeney, L; Foster, GR; Bhui, KS (2015-02-15)

INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY

Gill, US; Payaniandy, L; Payaniandy, D; Schulz, J; Ross, VA; Kallis, YN; Kooner, P; Marley, RTC; Kennedy, PTF; Foster, GR (2013-04)

Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B

Gill, US; Peppa, D; Singh, HD; Micco, L; Foster, GR; Maini, MK; Kennedy, PT (2014)

High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?

Orkin, C; Leach, E; Flanagan, S; Wallis, E; Ruf, M; Foster, GR; Tong, CYW (2015-10)

High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B

Hansi, NK; Gill, US; Banerjee, A; Surendraraj, N; Patel, C; Naik, S; Foster, GR; Kennedy, PT (2014)

Shorter treatments for hepatitis C: another step forward?

Foster, GR (2015-03-21)

1
2
3
4
. . .
9